Therefore, chemotherapeutic inhibition of overexpressed BIRC2-3 may provide the basis for an approach to develop a clinically realistic treatment of FA-HNSCCs that carry 11q22.2-3 amplifications [28]. This evidence concerns the gene BIRC2 and Friedreich ataxia.